Antibody–Drug Conjugates for Cancer Therapy
AbstractAntibody–drug conjugates (ADCs) take advantage of the specificity of a monoclonal antibody to deliver a linked cytotoxic agent directly into a tumour cell. The development of these compounds provides exciting opportunities for improvements in patient care. Here, we review the key issues impacting on the clinical success of ADCs in cancer therapy. Like many other developing therapeutic classes, there remain challenges in the design and optimisation of these compounds. As the clinical applications for ADCs continue to expand, key strategies to improve patient outcomes include better patient selection for treatment and the identification of mechanisms of therapy resistance. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Parslow, A.C.; Parakh, S.; Lee, F.-T.; Gan, H.K.; Scott, A.M. Antibody–Drug Conjugates for Cancer Therapy. Biomedicines 2016, 4, 14.
Parslow AC, Parakh S, Lee F-T, Gan HK, Scott AM. Antibody–Drug Conjugates for Cancer Therapy. Biomedicines. 2016; 4(3):14.Chicago/Turabian Style
Parslow, Adam C.; Parakh, Sagun; Lee, Fook-Thean; Gan, Hui K.; Scott, Andrew M. 2016. "Antibody–Drug Conjugates for Cancer Therapy." Biomedicines 4, no. 3: 14.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.